[go: up one dir, main page]

PE20151092A1 - Compuestos derivados de quinolina y quinoxalina como agentes antivirales - Google Patents

Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Info

Publication number
PE20151092A1
PE20151092A1 PE2015001204A PE2015001204A PE20151092A1 PE 20151092 A1 PE20151092 A1 PE 20151092A1 PE 2015001204 A PE2015001204 A PE 2015001204A PE 2015001204 A PE2015001204 A PE 2015001204A PE 20151092 A1 PE20151092 A1 PE 20151092A1
Authority
PE
Peru
Prior art keywords
dihydro
methoxy
tert
butyl
quinoxaline
Prior art date
Application number
PE2015001204A
Other languages
English (en)
Inventor
Jim Li
Ryan Craig Schoenfeld
Francisco Xavier Talamas
Joshua Paul Gergely Taygerly
Vicente Fidalgo Javier De
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20151092A1 publication Critical patent/PE20151092A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)

Abstract

Referida a compuestos especificos tales como N-{4-[6-tert-butil-2-metoxi-3-(2-oxo-1,2-dihidro-piridin-3-il) -quinolin-8-il] -fenil} -metanosulfonamida; N-{4-[6-tert-butil-8- (2,4-dioxo-3,4-dihidro-2H-pirimidin-1-il)-5-metoxi-quinolin-3-il]-fenil} -metanosulfonamida; N-{4-[6-tert-butil-5-metoxi-8-(6-metoxi-2-oxo-1,2-dihidro-piridin-3-il)-quinolin-3-il]-fenil} -metanosulfonamida; acido 2-[6-tert-butil-5-metoxi-8-(2-oxo-1,2-dihidro-piridin-3-il)-quinolin-3-il]-benzoico; N-{4-[7-tert-butil-5-(2,4-dioxo-3,4-dihidro-2H-pirimidin-1-il)-3-metil-quinoxalin-2-il]-3-cloro-fenil}-metano-sulfonamida; entre otros
PE2015001204A 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales PE20151092A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18546009P 2009-06-09 2009-06-09
US26335109P 2009-11-21 2009-11-21

Publications (1)

Publication Number Publication Date
PE20151092A1 true PE20151092A1 (es) 2015-08-06

Family

ID=42288900

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011002042A PE20120937A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales
PE2015001204A PE20151092A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2011002042A PE20120937A1 (es) 2009-06-09 2010-06-08 Compuestos derivados de quinolina y quinoxalina como agentes antivirales

Country Status (24)

Country Link
US (2) US8026253B2 (es)
EP (1) EP2440528B1 (es)
JP (1) JP5612678B2 (es)
KR (1) KR101431343B1 (es)
CN (1) CN102803216B (es)
AR (1) AR077004A1 (es)
AU (1) AU2010257592B2 (es)
BR (1) BRPI1010852A2 (es)
CA (1) CA2764141C (es)
CO (1) CO6400218A2 (es)
CR (1) CR20110605A (es)
EC (1) ECSP11011513A (es)
ES (1) ES2525254T3 (es)
IL (1) IL216412A (es)
MA (1) MA33360B1 (es)
MX (1) MX2011013209A (es)
MY (1) MY157435A (es)
NZ (1) NZ596646A (es)
PE (2) PE20120937A1 (es)
RU (1) RU2540332C2 (es)
SG (1) SG176762A1 (es)
TW (1) TWI428332B (es)
WO (1) WO2010142656A1 (es)
ZA (1) ZA201108921B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG174252A1 (en) * 2009-03-06 2011-10-28 Hoffmann La Roche Heterocyclic antiviral compounds
ES2481411T3 (es) * 2010-07-07 2014-07-30 F. Hoffmann-La Roche Ag Compuestos heterocíclicos antivíricos
BR112013003113A2 (pt) * 2010-08-13 2019-09-24 Hoffmann La Roche compostos antivirais heterocíclicos
WO2013090929A1 (en) * 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
SG11201502369XA (en) 2012-10-16 2015-05-28 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
WO2014062655A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv HETEROARYL LINKED QUINOLINYL MODULATORS OF RORyt
ES2628365T3 (es) 2012-10-16 2017-08-02 Janssen Pharmaceutica N.V. Moduladores de quinolinilo unidos a fenilo de ROR-GAMA-T
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
SG11201607973XA (en) * 2014-03-24 2016-11-29 Guangdong Zhongsheng Pharmaceutical Co Ltd Quinoline derivatives as smo inhibitors
CN108137514A (zh) * 2015-07-30 2018-06-08 百时美施贵宝公司 芳基取代的二环杂芳基化合物
US11613543B2 (en) 2018-03-26 2023-03-28 Novartis Ag Substituted pyrrolo[2,3-d]pyrimidines as Bruton's Tyrosine Kinase inhibitors
MX2021009764A (es) 2019-02-15 2021-09-08 Novartis Ag Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos.
EP4031243A1 (en) * 2019-09-16 2022-07-27 Novartis AG Glue degraders and methods of use thereof
WO2021198981A1 (en) 2020-04-01 2021-10-07 Janssen Biopharma, Inc. Antiviral compounds and uses thereof
CN111777549A (zh) * 2020-07-07 2020-10-16 中瀚(齐河县)生物医药科技有限公司 一种2-甲氧基-3-溴-5-氟吡啶的合成工艺
JP2023549738A (ja) * 2020-10-30 2023-11-29 1シーバイオ, インコーポレイテッド エクトヌクレオチドピロホスファターゼ-ホスホジエステラーゼ-1(enpp1)阻害物質及びそれらの使用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB558009A (en) * 1942-05-08 1943-12-15 Harold Coates Quinoline derivatives
RU2029472C1 (ru) * 1989-09-26 1995-02-27 Сумитомо Кемикал Компани Лимитед Производные урацила, промежуточные соединения, гербицидная композиция и способ борьбы с сорняками
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
EP1292310A1 (en) * 2000-05-10 2003-03-19 SmithKline Beecham Corporation Novel anti-infectives
WO2009032123A2 (en) 2007-08-29 2009-03-12 Schering Corporation Tetracyclic indole derivatives and their use for treating or preventing viral infections
MX2010002318A (es) 2007-08-29 2010-03-22 Schering Corp Derivados azaindol 2,3-sustituidos para tratar infecciones virales.
TW200924751A (en) 2007-08-29 2009-06-16 Schering Corp 2,3-substituted indole derivatives and methods of use thereof
ES2453591T3 (es) 2007-09-17 2014-04-08 Abbvie Bahamas Ltd. Derivado de uracilo o timina para el tratamiento de la hepatitis C
HRP20110809T1 (hr) 2007-09-17 2011-12-31 Abbott Laboratories Protuupalni pirimidini i njihove uporabe
EP2548873A1 (en) 2007-09-17 2013-01-23 Abbott Laboratories N-phenyl-dioxo-hydropyrimidines useful as hepatitis c virus (hcv) inhibitors
US8765757B2 (en) 2007-11-16 2014-07-01 Merck Sharp & Dohme Corp. 3-heterocyclic substituted indole derivatives and methods of use thereof
CA2705587A1 (en) 2007-11-16 2009-05-22 Schering Corporation 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CN105924386A (zh) 2009-03-25 2016-09-07 Abbvie 公司 抗病毒化合物和其用途
WO2010111437A1 (en) 2009-03-25 2010-09-30 Abbott Laboratories Antiviral compounds and uses thereof

Also Published As

Publication number Publication date
SG176762A1 (en) 2012-01-30
US8026253B2 (en) 2011-09-27
EP2440528A1 (en) 2012-04-18
NZ596646A (en) 2014-01-31
US8487103B2 (en) 2013-07-16
IL216412A (en) 2015-01-29
ZA201108921B (en) 2014-05-28
CA2764141A1 (en) 2010-12-16
US20100311760A1 (en) 2010-12-09
AU2010257592B2 (en) 2014-11-13
TWI428332B (zh) 2014-03-01
MY157435A (en) 2016-06-15
WO2010142656A1 (en) 2010-12-16
BRPI1010852A2 (pt) 2019-09-24
ES2525254T3 (es) 2014-12-19
US20110300103A1 (en) 2011-12-08
CO6400218A2 (es) 2012-03-15
HK1176070A1 (zh) 2013-07-19
CR20110605A (es) 2012-02-09
MA33360B1 (fr) 2012-06-01
AU2010257592A1 (en) 2011-12-15
PE20120937A1 (es) 2012-08-01
KR20120016675A (ko) 2012-02-24
JP5612678B2 (ja) 2014-10-22
RU2011153788A (ru) 2013-07-20
IL216412A0 (en) 2012-02-29
TW201103906A (en) 2011-02-01
RU2540332C2 (ru) 2015-02-10
CN102803216B (zh) 2016-04-06
ECSP11011513A (es) 2012-01-31
CN102803216A (zh) 2012-11-28
EP2440528B1 (en) 2014-10-08
JP2012529461A (ja) 2012-11-22
AR077004A1 (es) 2011-07-27
MX2011013209A (es) 2012-01-09
CA2764141C (en) 2016-11-15
KR101431343B1 (ko) 2014-08-19

Similar Documents

Publication Publication Date Title
PE20151092A1 (es) Compuestos derivados de quinolina y quinoxalina como agentes antivirales
EP2635284A4 (en) Heterocyclic compounds and their use
EP2575462A4 (en) Heterocyclic compounds and their use
PT2806859T (pt) Formulações de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiridin-2-il)benzoico
EP2467141A4 (en) Heterocyclic compounds and their use
MA37519B1 (fr) Composés et compositions pour inhiber l'activité d'abl1, abl2 et bcr-abl1
EP2878033A4 (en) AQUEOUS REDOX FLOW BATTERIES WITH METAL LIGAND COORDINATION COMPOUNDS
EP2921480A4 (en) NITROGENIC HETEROCYCLIC COMPOUND
EP2917184A4 (en) ALTERNATIVE USES FOR HBV ARRANGEMENT EFFECTORS
MD20140124A2 (ro) Compuşi inhibitori ai activităţii catehol O-metiltransferazei
EP2804851A4 (en) THERAPEUTIC ACTIVE SUBSTANCES AND METHOD FOR THEIR USE
EP2594567A4 (en) HETEROCYCLIC ALKINYL BENZENE COMPOUNDS AND MEDICAL COMPOSITIONS AND THEIR USES
EA201391822A1 (ru) Новые производные пиридина
EP2687507A4 (en) NITROGENIC CONDENSED HETEROCYCLIC COMPOUND
PE20121153A1 (es) Quinazolinas como inhibidores de los canales ionicos de potasio
EP2802035A4 (en) BATTERY PACK WITH NOVEL AIR COOLING STRUCTURE
LT3575264T (lt) Energijos atgavimas gaminant sieros rūgštį
BRPI0922489A2 (pt) amida de ácido 4-(1,2,3,4-tetrahidroisoquinolina-2-il)-4-oxobutírico como modulares de kcnq2/3
EP2927214A4 (en) NITROGENIC HETEROCYCLIC COMPOUND
BR112014023957A2 (pt) agonistas dos receptores adrenérgicos alfa-2
PE20142445A1 (es) Compuestos de pirazol sustituidos como antagonistas de lpar
ME03018B (me) Jedinjena uree i njhova upotreba као inhibitora enzima
LT3395796T (lt) (3s,3s') 4,4'-disulfandiil-bis-(3-aminobutan-1-sulfonrūgšties) kristalinė trihidrato forma
CO6580197A1 (es) Procedimiento de sisntesis y forma cristalina del hidrocloruro de 4-{3-[cis-hewahidrociclopenta[c]pirrol} -2(1h)-il]propoxi}benzamida así como las composiciones farmaceuticas que la contienen
PH12015501798A1 (en) Processes for the preparation of bispyribac sodium and intermediates thereof

Legal Events

Date Code Title Description
FC Refusal